Check out some of the medications affected by drugmakers raising prices on life-saving medications this year, as well as some ...

President Donald Trump has locked in a sweeping set of pricing agreements with nine of the world's biggest drugmakers, promising to pull some of the most expensive medicines on the U.S. market closer ...

Dec 23 (Reuters) - A patient who was being treated with Pfizer's (PFE.N), opens new tab hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the ...

FILE PHOTO: A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo Dec 23 (Reuters) - A ...

Pfizer (PFE) on Tuesday announced that a patient who was taking part in a long-term extension trial for its hemophilia therapy Hympavzi (marstacimab) died after serious adverse events. The patient ...

Investing.com -- A patient died after receiving Pfizer Inc.’s (NYSE:PFE) hemophilia drug Hympavzi, adding to challenges for the company in blood disorder treatments. The death occurred on December 14 ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders. The death occurred on Dec. 14 after the patient ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...